News 2018 | Strand Life Sciences

Strand Life Sciences Acquires India Diagnostics Business from Quest Diagnostics

https://strandls.com/wp-content/themes/osmosis/images/empty/thumbnail.jpg 150 150 Strand Life Sciences Strand Life Sciences https://secure.gravatar.com/avatar/a6ea35408ed49604a9b4794bbe46001b?s=96&d=mm&r=g October 6, 2018 October 10, 2018

By: Strand Life Sciences

October 6, 2018

October 6, 2018 | Bangalore Strand Life Sciences announced an agreement to acquire the India medical diagnostics business of Quest Diagnostics, the world’s leading…

High Prevalence of Hereditary Breast and/or Ovarian Cancer Among Patients in India

By: Strand Life Sciences

March 13, 2018

A study conducted by Strand Life Sciences shows that in the Indian population, there is a high prevalence of germline mutations in the BRCA1, BRCA2, TP53 and PALB2 genes March…

Strand Life Sciences Closes Financing Led By Quadria Capital

https://strandls.com/wp-content/themes/osmosis/images/empty/thumbnail.jpg 150 150 Maria Kammerer Maria Kammerer https://secure.gravatar.com/avatar/80a8f7516b90fbc7747e96ab4b441bd9?s=96&d=mm&r=g February 8, 2018 February 8, 2018

By: Maria Kammerer

February 8, 2018

February 8, 2018 | Bangalore Strand Life Sciences announced an investment by Quadria Capital, Asia’s leading healthcare focused private equity investor. India-based HealthQuad Fund…

Triesta Unit of HCG to Combine with Strand Life Sciences

By: Strand Life Sciences

January 4, 2018

Strategic initiative creates integrated platform dedicated to next generation precision medicine January 4, 2018 | Bengaluru, India Healthcare Global Enterprises, Ltd. (HCG:NSE) today…